3rd Feb 2021 09:48
(Alliance News) - Scancell Holdings PLC on Wednesday announced the end of its clinical development partnership with charity Cancer Research UK for SCIB2, a treatment for patients with solid tumours.
Scancell shares were down 6.7% at 13.30 pence each in London on Wednesday morning.
The Oxford-based novel immunotherapies developer said that due to the impact of the Covid-19 pandemic and Cancer Research UK's centre for drug development's re-evaluation of their collaboration model, "the parties have come to a mutual agreement" to end their partnership for the company's "ImmunoBody" vaccine, or SCIB2.
Under the terms of the partnership, inked in December 2017, Cancer Research UK were due to fund and sponsor a phase 1 and 2 clinical trial of SCIB2 in patients with solid tumours.
Scancell's "ImmunoBody" immunotherapy platform activates the body's immune system by enhancing the uptake of cancer antigens, similar to antibodies, to help target and eliminate cancer cells.
SCIB2 product rights will now revert to Scancell with no further commercial obligations to Cancer Research UK, Scancell said.
Scancell Chief Executive Cliff Holloway said: "We have enjoyed working with the team at Cancer Research UK but will now explore further options to advance the SCIB2 programme which we believe has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours."
By Greg Roxburgh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings